CUE · ISSUER CIK 1645460
Cue Biopharma, Inc.
Between Aug 1, 2026 and Oct 29, 2026, 4 Cue Biopharma, Inc. insiders reported $0.00 of open-market purchases and $2.4M of sales on SEC Form 4.
↗4 insiders filed
Original Form 4 filings from Aug 1, 2026 to Oct 29, 2026. 0 of 6 sales were reported under a 10b5-1 plan.
$0.00Insider buying
$2.4MInsider selling
−$2.4MNet open-market
Oct 14, 2026Latest filing
| Ticker | Insider | Type | Owned | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 202621:39 | Oct 12, 2026 | CUE | Chief Legal Compliance Officer, Corporate Secretary | S · Sell | $28.05 | −1,844 | 116,701 | -2% | −$52K | ||
| Oct 14, 202621:38 | Oct 12, 2026 | CUE | VP, Prin. Accounting Officer | S · Sell | $28.05 | −1,144 | 47,817 | -2% | −$32K | ||
| Oct 14, 202621:37 | Oct 12, 2026 | CUE | Chief Executive Officer, Director | S · Sell | $27.55 | −11,087 | 694,908 | -2% | −$305K | ||
| Aug 17, 202618:22 | Aug 13, 2026 | CUE | Chief Legal Compliance Officer, Corporate Secretary | S · Sell | $30.09 | −8,829 | 118,545 | -7% | −$266K | ||
| Aug 17, 202618:22 | Aug 13, 2026 | CUE | Chief Legal Compliance Officer, Corporate Secretary | M · Exercise | — | +18,196 | 127,374 | +17% | — | ||
| Aug 17, 202618:19 | Aug 13, 2026 | CUE | VP, Prin. Accounting Officer | S · Sell | $30.09 | −5,628 | 48,961 | -10% | −$169K | ||
| Aug 17, 202618:19 | Aug 13, 2026 | CUE | VP, Prin. Accounting Officer | M · Exercise | — | +13,647 | 54,589 | +33% | — | ||
| Aug 14, 202620:46 | Aug 13, 2026from Aug 12, 2026 | CUE | Chief Executive Officer, Director | S · Sell | $27.58 | −58,258 | 705,995 | -8% | −$1.6M | ||
| Aug 14, 202620:46 | Aug 12, 2026 | CUE | Chief Executive Officer, Director | M · Exercise | — | +109,179 | 764,253 | +17% | — | ||
| Aug 3, 202616:19 | Jul 30, 2026 | CUE | Chief Financial Officer | A · Grant | — | +25,500 | 25,500 | New | — |